8-K: Anebulo Reports Q4/FY25 Results, Shifts Focus to IV Selonabant

Anebulo Pharmaceuticals announced its Q4 and fiscal year 2025 financial results, highlighting a strategic pivot to an intravenous selonabant formulation for pediatric cannabis toxicity and a proposed reverse stock split for a potential going-private transaction.

Summary

• Reported financial results for the fourth quarter and fiscal year ended June 30, 2025.
• Initiated a Phase 1 single ascending dose (SAD) study for an intravenous (IV) formulation of its lead drug candidate, selonabant, on September 25, 2025, targeting acute cannabis-induced toxicity in children.
• Awarded the second-year tranche of a $994,300 collaborative grant from the National Institute on Drug Abuse (NIDA) to support the ongoing SAD study.
• Prioritized the advancement of IV selonabant for pediatric patients over the adult oral product, believing it offers a faster timeline to approval.
• A Special Committee and Board of Directors approved a proposed reverse stock split, subject to stockholder approval, to maintain fewer than 300 record holders and avoid SEC public reporting requirements as part of a potential going-private transaction.
• Operating expenses for Q4 FY2025 were $2.3 million, an increase from $1.3 million in Q4 FY2024.
• Net loss for Q4 FY2025 was $2.1 million, or $(0.05) per share, compared to a net loss of $1.3 million, or $(0.05) per share, in Q4 FY2024.
• Operating expenses for fiscal year 2025 were $9.2 million, up from $8.3 million in fiscal year 2024.
• Net loss for fiscal year 2025 was $8.5 million, or $(0.25) per share, compared to a net loss of $8.2 million, or $(0.32) per share, in fiscal year 2024.
• Cash and cash equivalents stood at $11.6 million as of June 30, 2025, with access to an additional $3 million through a Loan Agreement.

Sentiment

Score: 5

Explanation: While clinical development for selonabant in pediatric cannabis toxicity is progressing positively with grant funding and FDA collaboration, the increased net loss and operating expenses, coupled with the proposed reverse stock split and potential going-private transaction, introduce significant uncertainty and negative implications for public shareholders, balancing the overall sentiment to neutral.

Positives

• Initiated a Phase 1 SAD study for an IV formulation of selonabant for acute cannabis-induced toxicity in children, addressing a significant unmet medical need.
• Received the second-year tranche of a $994,300 NIDA grant, providing non-dilutive funding for the ongoing SAD study.
• FDA has suggested close collaboration to facilitate the development of selonabant for pediatric cannabis toxicity, indicating regulatory support.
• Cash and cash equivalents increased significantly to $11.6 million as of June 30, 2025, from $3.1 million in the prior fiscal year.
• Has access to an additional $3 million in cash through a Loan Agreement, enhancing liquidity.
• Net loss per share improved to $(0.25) in FY2025 from $(0.32) in FY2024, despite an increased net loss, due to higher weighted average shares outstanding.

Negatives

• Operating expenses increased in both Q4 FY2025 ($2.3 million vs $1.3 million) and FY2025 ($9.2 million vs $8.3 million), indicating higher cash burn.
• Net loss increased in both Q4 FY2025 ($2.1 million vs $1.3 million) and FY2025 ($8.5 million vs $8.2 million).
• The proposed reverse stock split and potential going-private transaction could lead to delisting and significantly reduced liquidity and transparency for current public shareholders.
• Uncertainty surrounds the outcome of the strategic alternatives review process and whether the reverse stock split will ultimately be abandoned, even if approved by stockholders.

Risks

• Ability to pursue the regulatory strategy, including the Phase 1 SAD study of intravenous selonabant.
• The ability of selonabant to be an effective treatment for pediatric patients with cannabis-induced CNS depression.
• The ability of selonabant to rapidly reverse key symptoms of cannabis toxicity, including acute cannabis-induced toxicity in children.
• The ability of a selonabant IV formulation to offer a faster timeline to approval relative to the adult oral product.
• Ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements.
• Ability to obtain or maintain the capital or grants necessary to fund research and development activities.
• Ability to complete clinical trials on time and achieve desired results and benefits as expected.
• Regulatory limitations relating to the ability to promote or commercialize product candidates for specific indications.
• Acceptance of product candidates in the marketplace and the successful development, marketing, or sale of products.
• Ability to maintain license agreements.
• The continued maintenance and growth of the patent estate.
• Ability to retain key employees.
• No assurance that the strategic review process will result in the company pursuing a transaction or any other strategic outcome.
• The Board could determine to abandon the Reverse Stock Split for any reason, even if stockholders approve it.

Future Outlook

Anebulo expects research and development expenses to increase as it completes the current Phase 1 SAD study and prepares for further clinical trials. The company believes the IV formulation for pediatric patients offers the potential for a faster timeline to approval compared to the adult oral product. The strategic review process for alternatives is ongoing, with no definitive timetable, and there is no assurance it will result in a transaction or any other strategic outcome.

Management Comments

• "We have made significant progress towards our goal of providing the first emergency antidote for acute cannabis-induced toxicity in children."
• "In addition to the continuing collaborative support from NIDA, our interactions with the Food and Drug Administration to date have confirmed our belief that there is a significant and growing unmet need for a treatment for children exposed to cannabis toxicity."
• "FDA has suggested a close collaboration with Anebulo to facilitate the development of selonabant for this important pediatric condition."
• "If approved, we believe selonabant has the potential to offer a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of acute cannabis-induced toxicity in children."

Industry Context

The filing highlights a growing unmet medical need for a specific antidote for acute cannabis-induced toxicity, particularly in children, which is becoming more prevalent with increasing cannabis legalization and exposure. The strategic focus on an IV formulation for pediatric use positions Anebulo to address a critical emergency care gap, potentially differentiating it from companies focused solely on adult or recreational use. The collaboration with NIDA and FDA engagement underscore the recognized public health importance of this therapeutic area.

Comparison to Industry Standards

• The filing emphasizes the 'significant and growing unmet need' for a treatment for children exposed to cannabis toxicity, suggesting a lack of established therapies or direct competitors in this specific pediatric emergency care niche.
• Anebulo believes selonabant has the potential to offer a 'much-needed targeted therapy' and be the 'first emergency antidote' for acute cannabis-induced toxicity in children, implying a pioneering role rather than a comparison to existing benchmarks.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for reduced liquidity and transparency if the company goes private, and the impact of a reverse stock split on share price and ownership structure. Uncertainty regarding the strategic review process.
• Patients (Pediatric): Potential for a much-needed targeted therapy for acute cannabis-induced toxicity, addressing a significant unmet medical need.
• Employees: Continued research and development activities and potential for a successful drug development program.
• NIDA/NIH: Continued collaboration and grant funding for research into cannabis-induced toxicity.

Next Steps

• Complete the Phase 1 SAD study for IV selonabant.
• Prepare for further clinical trials for IV selonabant.
• Hold a special meeting of stockholders to approve the Reverse Stock Split.
• Continue the strategic alternatives review process.
• Amend the ongoing observational study in Emergency Departments to focus on pediatric patients.

Key Dates

Recommendation

The proposed reverse stock split and the explicit intention to maintain fewer than 300 record holders to avoid SEC public reporting requirements, as part of a potential going-private transaction, are highly detrimental to public shareholders. This move signals a significant reduction in transparency and liquidity, making the stock unattractive for public investment. While clinical progress with selonabant is positive, the corporate governance decision to potentially delist and go private overshadows any therapeutic advancements for public investors, warranting a 'sell' recommendation.

Keywords

Anebulo Pharmaceuticals, ANEB, selonabant, cannabis toxicity, pediatric treatment, IV formulation, NIDA grant, Phase 1 study, acute cannabinoid intoxication, ACI, reverse stock split, going private, financial results, Q4 2025, FY 2025, pharmaceutical, clinical-stage, drug development